en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
1/2022
vol. 97
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Opis przypadku

Clinical manifestations, toxicities, and outcome of two children with Nijmegen breakage syndrome and lymphoid malignancies – case reports

Aleksandra Filipiuk
1
,
Agata Kozakiewicz
1
,
Kamil Kośmider
1
,
Katarzyna Karska
2
,
Monika Lejman
3
,
Joanna Zawitkowska
2

  1. Student Scientific Society, Department of Paediatric Haematology, Oncology, and Transplantology, Medical University of Lublin, Poland
  2. Department of Paediatric Haematology, Oncology, and Transplantology, Medical University of Lublin, Poland
  3. Laboratory of Genetic Diagnostics, Department of Paediatric Haematology, Oncology, and Transplantology, Medical University of Lublin, Poland
Pediatr Pol 2022; 97 (1): 48–52
Data publikacji online: 2022/03/23
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Nijmegen breakage syndrome (NBS) is a rare disease with an autosomal recessive pattern of inheritance caused by mutations in the NBN gene.

We report 2 patients with NBS and T-cell lymphoblastic lymphoma (T-LBL), in whom diagnosis and therapy were difficult challenges. Both patients were diagnosed with NBS by mutation analysis of the NBN gene, which revealed homozygosity for a typical 5 base pair deletion (657del5). The lymph node biopsy revealed T-LBL, and both patients were treated according to EURO-LB 02. Complete remission was achieved in the first patient. In the second case, bone marrow relapse was observed, and the patient died due to disease progression.

In conclusion, patients with NBS should be closely monitored because of a higher frequency of lymphoma than in the general population. The described cases indicate the importance of identifying predictive markers of cancers and developing treatment regimens for patients with NBS and malignancies.